Beam Therapeutics BEAM
NASDAQ BEAM
$25.81 +0.66 (+2.62%)
At close: Nov 11, 2026 · 4:00 PM EST

Beam Therapeutics (BEAM) Gains from Sales and Divestitures (2026)

Updated

Analysis

Beam Therapeutics (BEAM) Gains from Sales and Divestitures (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Beam Therapeutics 2.60 Bn -2.05 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 1,000.00
API Access

Beam Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=BEAM&period=max&api_key=YOUR_API_KEY